Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthHealth New England TMS Prior Auth Update | OpenPay…
    Ask Trek AI about this page
    CurrentHealth-New-EnglandPolicy UM917POL

    Transcranial Magnetic Stimulation (TMS) - Behavioral Health Policy

    Customize your policy alerts

    Sign up for Health-New-England Policy UM917POL alerts

    Get alerted when Policy UM917POL changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity review for initial and repeat TMS treatment of major depressive disorder for Health New England Commercial and Medicare Advantage members. Commercial members are reviewed under the policy criteria, while Medicare members follow LCD L33398; Medicaid/BeHealthy medical-necessity review is performed by MBHP.

    Policy Summary
    PayerHealth-New-England
    PolicyTranscranial Magnetic Stimulation (TMS) - Behavioral Health Policy
    Policy CodePolicy UM917POL
    Change TypeRevised
    Effective DateAug 1, 2026
    Last ReviewMar 1, 2024
    Next Review DateNot specified
    Key ActionObtain prior authorization for CPT 90867, 90868, and 90869 before providing TMS.
    SourceLink
    POLICY UPDATE CHANGES

    The psychopharmacologic-resistance criteria were updated to require two or more medication trials from at least two different antidepressant classes during the current depressive episode.

    The policy clarified that approved TMS services are authorized for 12 weeks from the requested start date.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 weeksStandard authorization period
    1 / 35 / 1Standard approved units
    2 classesMinimum antidepressant classes
    6 weeksMedication trial duration
    >50%Prior TMS improvement for repeat treatment
    ExperimentalMaintenance TMS coverage

    Medical Necessity and Coverage Criteria

    Initial TMS for major depressive disorder

    Initial TMS is covered when all criteria are met.

    Initial TMS criteria

    • Diagnosis: Confirmed current DSM-5 diagnosis of severe major depressive disorder, single or recurrent episode, without psychotic features.

      The policy identifies ICD-10 codes F32.2 or F33.3 with the diagnosis statement.

    • Psychotherapy: An adequate trial of evidence-based psychotherapy known to be effective for major depressive disorder was completed during the current episode without significant improvement in depressive symptoms.At least one weekly session for at least 12 weeks

      Examples include cognitive behavioral, interpersonal, or psychodynamic therapy.

    • Psychopharmacologic resistance or intolerance

      • Inadequate response: There was a lack of clinically significant response to two or more trials of psychopharmacologic agents from at least two different classes of antidepressant medications during the current episode.At least 2 trials; at least 6 weeks each; at least 2 antidepressant classes

        Document medication adherence or reasons for inability to take medication, as applicable.

      • Intolerance: The member was unable to tolerate psychopharmacologic agents, as demonstrated by two recent trials from at least two different classes of antidepressant medications with distinct side effects.2 recent trials; at least 2 antidepressant classes; distinct side effects
    • Outcome monitoring: Validated depression monitoring scales are administered at the beginning and end of the initial and each subsequent course of TMS.

      Examples include HAM-D, MADRS, PHQ-9, BDI, or another appropriate tool.

    • ECT history or discussion: The member was either offered and declined a trial of ECT during the current episode when clinically appropriate, or has a history of nonresponse or adverse effects from ECT.
    • Referral and submission: The referral is initiated by an ongoing licensed provider, and the TMS Prior Authorization form is submitted by the ongoing psychiatric provider or by a potential TMS psychiatrist who has completed a full evaluation and determined that the member is an appropriate candidate for TMS.

      Identify the referring provider on the form. If the potential TMS psychiatrist submits the request, attach that psychiatrist's full evaluation. Include dates, doses, and responses for recent psychiatric medication trials and psychotherapy.

    Repeat TMS for acute relapse

    Repeat TMS for an acute relapse is covered when both criteria are met.

    Repeat TMS criteria

    • Initial criteria: All criteria for initial TMS therapy are met.
    • Prior response: The member had more than 50% improvement during a prior TMS treatment episode or episodes, as demonstrated by a validated rating scale for depressive symptoms.>50% improvement

    Device and contraindication requirements

    TMS treatment must use an appropriately cleared or approved device, and potential contraindications must be evaluated before treatment.

    Device and safety requirements

    • FDA device status: The TMS device is FDA approved or FDA cleared for treatment of major depressive disorder.
    • Contraindication review: The provider considers seizure disorder or any history of seizures, current psychotic symptoms in the depressive episode, specified neurologic conditions, nearby magnetic-sensitive implants or other implanted metal, pregnancy or nursing, a current suicide plan or recent suicide attempt, current or recent substance use disorder, eating disorder or posttraumatic stress disorder, and any history of bipolar disorder or psychotic disorder.

      Neurologic concerns include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, repetitive or severe head trauma, and primary or secondary CNS tumors. Implanted concerns include devices or metal items within 30 cm of the TMS coil, such as cochlear implants, ICDs, pacemakers, vagus nerve stimulators, and metal aneurysm clips, coils, staples, or stents. Dental amalgam fillings are acceptable.

    • Rationale when a contraindication is present:

    Maintenance TMS for depression is considered experimental and investigational because its effectiveness and safety have not been established. Therefore, maintenance TMS is not covered.

    Coding and Clinical Thresholds

    TMS CPT codes requiring prior authorizationCPT
    90867Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management.
    90868Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session.
    90869Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management.
    Medication trial
    Minimum durationAt least 6 weeks per medication trial
    Required inadequate-response trialsTwo or more psychopharmacologic-agent trials
    Antidepressant classesTrials must be from at least two different classes of antidepressant medications
    Psychotherapy trial
    Therapy typeEvidence-based psychotherapy effective for major depressive disorder
    FrequencyAt least one session weekly
    Minimum duration

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization and Standard Unit Limits

    Prior authorization is required for CPT 90867, 90868, and 90869. For Commercial and Medicare services, the standard approval is 1 unit of 90867, 35 units of 90868, and 1 unit of 90869 for 12 weeks; additional units require supporting documentation and case-by-case review.

    • 90867: 1 unit
    • 90868: 35 units
    • 90869: 1 unit
    • Additional units require documentation and case-by-case review.
    • All three codes require PA.
    Note

    Line-of-Business Review Pathway

    The review pathway depends on the member's line of business. Commercial requests are reviewed under this policy's criteria; Medicare requests follow CMS Local Coverage Determination (LCD) L33398, Transcranial Magnetic Stimulation. The supplied policy text does not specify a separate Medicaid/BeHealthy pathway, so apply the applicable Medicaid/BeHealthy authorization requirements.

    Clinical Background

    Transcranial magnetic stimulation (TMS) is a noninvasive brain-stimulation procedure that uses a coil placed over the scalp to generate a magnetic field that passes through the brain. The rapidly alternating field is directed to targeted cortical regions.

    Definitions

    Transcranial magnetic stimulation (TMS)
    TechniqueA noninvasive method of brain stimulation
    Scalp coilA small coil is placed over the scalp
    Magnetic field and penetrationA rapidly alternating current through the coil produces a magnetic field that passes unimpeded through the brain
    Repetitive TMS (rTMS)
    Stimulation patternRepetitive TMS uses repeated magnetic stimulation
    Targeted regionsSpecific cortical regions, including the left dorsolateral prefrontal cortex and deep cortical targets
    Effect

    TMS Treatment Modalities

    Transcranial magnetic stimulation (TMS)

    TMS is considered for severe, nonpsychotic major depressive disorder when required psychotherapy and antidepressant trials have not produced sufficient improvement or are not tolerated, required monitoring and provider documentation are present, and treatment is delivered with an FDA-approved or FDA-cleared device.

    TMS treatment criteria

    • Treatment course

      • Initial treatment: The member has a confirmed current DSM-5 diagnosis of severe major depressive disorder, single or recurrent episode, without psychotic features; has completed the required psychotherapy and qualifying antidepressant trials or demonstrated medication intolerance; has required validated symptom monitoring and ECT consideration; and has an appropriate ongoing-provider referral and prior authorization submission.
      • Repeat treatment for acute relapse: The member meets all criteria for initial TMS and had more than 50% improvement during a prior TMS treatment episode or episodes, demonstrated by a validated depressive-symptom rating scale.>50% prior improvement

    Authorization and Visit Limits

    TMS treatment
    Prior authorizationRequired for CPT 90867, 90868, and 90869
    CPT 908671 unit
    CPT 9086835 units
    CPT 908691 unit
    Authorization periodServices are approved for 12 weeks
    Additional unitsRequire supporting documentation and case-by-case review
    Policy Summary
    PayerHealth-New-England
    PolicyTranscranial Magnetic Stimulation (TMS) - Behavioral Health Policy
    Policy CodePolicy UM917POL
    Change TypeRevised
    Effective DateAug 1, 2026
    Last ReviewMar 1, 2024
    Next Review DateNot specified
    Key ActionObtain prior authorization for CPT 90867, 90868, and 90869 before providing TMS.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundDefinitionsTMS Treatment ModalitiesAuthorization and Visit Limits
    If a listed potential contraindication is present, the provider submits an adequate clinical rationale to HNE supporting the safety and appropriateness of proceeding with TMS.
    At least 12 weeks
    Prior TMS response
    Prior responseMore than 50% improvement during a prior TMS treatment episode or episodes
    MeasurementValidated rating scale for depressive symptoms
    Repeat-treatment contextRequired for repeat TMS treatment for an acute relapse, in addition to meeting all initial-therapy criteria
    • Commercial: use the criteria in this medical policy.
    • Medicare Advantage: follow LCD L33398 and applicable Medicare requirements.
    • Medicaid/BeHealthy: verify and follow the applicable program-specific pathway.
    Documentation Required

    Clinical Evaluation and Safety Assessment

    Document a face-to-face psychiatric evaluation confirming that DSM-5 diagnostic criteria for major depressive disorder are met. The record must also address current medications, medical conditions that may increase TMS risk, potential contraindications, and patient education regarding risks and benefits, including seizure risk.

    • Confirm the diagnosis and severity of MDD.
    • Assess prescribed medications and factors that may lower the seizure threshold.
    • Evaluate medical conditions and potential contraindications.
    • Document education about TMS risks and benefits.

    Unsupported block type: prior_auth

    Documentation Required

    Validated Symptom Measurement

    Use a validated depression monitoring scale at the beginning and end of the initial TMS course and each subsequent course. Include the results in the authorization record, including documentation supporting repeat treatment.

    • Acceptable tools include HAM-D, MADRS, PHQ-9, BDI, or another appropriate validated scale.
    • Record baseline and end-of-course results for the initial course.
    • Record baseline and end-of-course results for every subsequent course.
    • Use the results to demonstrate response to prior TMS when requesting repeat treatment.
    Documentation Required

    Contraindication Rationale Required

    Before proceeding, evaluate every listed potential contraindication. When treatment proceeds despite an applicable contraindication, submit an adequate clinical rationale explaining the safety and appropriateness of TMS in that member.

    • Consider seizure disorder or seizure history; current psychotic symptoms; neurological disease or CNS conditions; and magnetic-sensitive or other implanted metal devices.
    • Consider pregnancy or nursing, current suicide plan or recent suicide attempt, and current or recent substance use, eating, or posttraumatic stress disorder.
    • Consider any history of bipolar disorder or psychotic disorder, including schizophrenia and schizoaffective disorder.
    • Document the clinical rationale, risk-benefit assessment, and safety basis for proceeding.
    Denial Risk

    Maintenance TMS Is Not Covered

    Maintenance TMS for depression is considered experimental and investigational because effectiveness and safety have not been established. It is not a covered service under this policy.

    • Do not request maintenance TMS as covered treatment for depression.
    • Repeat TMS may be covered for an acute relapse only when the repeat-therapy criteria are met.
    Denial Risk

    Unaddressed Contraindications May Result in Denial

    An applicable contraindication cannot be left unaddressed in the authorization request. If the provider proceeds with TMS despite a listed potential contraindication, an adequate clinical rationale must be submitted to HNE; absent or inadequate rationale creates a denial risk.

    • Explicitly state whether each relevant contraindication is present, absent, or clinically addressed.
    • Explain why the expected benefits outweigh the identified safety risks.
    • Include the rationale with the PA request before treatment proceeds.
    Denial Risk

    Incomplete Initial-Therapy Criteria

    Initial TMS is at risk for denial when the record does not establish the required diagnosis and current-episode treatment history. Confirm all initial-therapy requirements before submitting the request.

    • Confirmed severe MDD, single or recurrent episode, without psychotic features.
    • Adequate evidence-based psychotherapy without significant improvement.
    • Resistance to or inability to tolerate antidepressants from at least two different classes, supported by the required trials and durations.
    • Validated depression scale results at the beginning and end of treatment.
    • Appropriate ECT history: offered and declined when clinically appropriate, or prior nonresponse/adverse effects.
    • Required referring provider and PA form documentation.
    Denial Risk

    Repeat-Therapy Criteria Must Be Met

    Repeat TMS for an acute depressive relapse is covered only when all initial-therapy criteria are met and the member had more than 50% improvement during prior TMS, documented by a validated depressive-symptom rating scale. Missing either element creates a denial risk.

    • Re-establish every applicable initial-therapy criterion for the current request.
    • Submit validated evidence of more than 50% improvement during the prior TMS episode or episodes.
    • Do not substitute maintenance treatment for medically necessary repeat treatment after an acute relapse.
    Depending on stimulation parameters, rTMS can increase or decrease the excitability of affected brain structures
  1. Device and contraindications

    • FDA device status: The TMS device is FDA approved or FDA cleared for treatment of major depressive disorder.
    • Safety review: The provider considers seizure history, current psychotic symptoms, specified neurologic conditions, magnetic-sensitive implants or other implanted metal near the coil, pregnancy or nursing, current suicide plan or recent suicide attempt, current or recent substance use disorder, eating disorder or posttraumatic stress disorder, and any history of bipolar or psychotic disorder.
    • Clinical rationale: When a listed potential contraindication is present, the provider submits an adequate clinical rationale supporting the safety and appropriateness of proceeding with TMS.